This study investigates the effect of publicity on consumer demand. Although the marketing literature suggests that publicity can have an important influence on consumers' choices, only a few studies have attempted to quantify how media coverage can affect consumer demand. The main obstacle to measuring the impact of publicity is that data on media coverage are difficult to interpret. To overcome this obstacle, we develop an algorithm to collect information presented in news articles and to map this information into a multi-dimensional attribute space. By applying our algorithm to news articles covering statins (a class of anti-cholesterol drugs) accessible in Canada from 1993-2004, we find evidence that media coverage plays a role in influencing physicians' choice of statins. Our results suggest that not all forms of publicity are equal. We find that comparison articles are much more effective than non-comparison articles. Moreover, we find that the most effective type of publicity is to provide information on the cholesterol-lowering ability of the drug, and the second most effective type of publicity is about side-effects. Surprisingly, despite the fact that the ultimate goal of taking anti-cholesterol medication is to reduce risks of heart disease, publicity related to this dimension has very little impact on demand. We also find evidence that physicians/patients may generalize clinical evidence on individual drug specific ability to reduce heart disease risks to the whole class of statins.
Introduction
Publicity is an important marketing communication tool for firms. It could have a strong impact on public awareness at a considerably lower cost than advertising, and function as a substitute/complement for direct-to-consumer advertising (DTCA). 1 Furthermore, consumers may give more credence to publicity than to advertising, since publicity is generally conveyed to consumers in the form of news. Despite its potential importance, previous research in marketing seldom investigated how publicity affects demand. This is mainly because collecting publicity data and interpreting them is very challenging. This paper contributes to the literature by (i) proposing a new method to interpret publicity data by mapping the information in each news article (or broadcast) to a multi-dimensional attribute space, and (ii) investigating how different types of publicity affect consumers' demand, in particular, in the context of prescription drugs.
More specifically, we study the impact of publicity on the demand for a class of prescription drugs called statins, which are the most commonly used anti-cholesterol drugs. There are several reasons why we study this market. First, there are large amounts of publicity surrounding this class of drugs, much of it related to post-marketing clinical studies (Sillup and Porth, 2008) . Second, it is plausible that patients and physicians become informed about their efficacy and side-effects through the media that they have access, e.g., newspapers, professional magazines, etc. Third, this is an important market for public health and firms' profitability. In the past decade, the most common cause of death is heart disease. 2 Medical research has consistently found a positive correlation between high cholesterol levels and risks of coronary heart disease. Because statins are effective in lowering cholesterol levels, it has been viewed as a way to reduce risks of heart disease and its demand has expanded very rapidly. From the public policy standpoint, it is useful to know if media coverage would lead physicians to choose a drug that has the strongest clinical evidence of reducing risks of heart disease at the time. From the 1 Principle of Marketing 7th edition, Chapter 15, Philip Kotler, Gary Amstrong and Peggy H. Cunningham 2 Public Health Agency of Canada ( http://www.phac-aspc.gc.ca/publicat/lcd-pcd97/table1-eng.php ) firms' standpoint, understanding how the demand side perceives publicity could also help them design their marketing campaign more efficiently.
Previous work has classified news stories as positive, negative, or neutral in a single dimension (Berger et al., 2010; Chintagunta et al., 2009; Goldenberg et al., 2007; Huang and Chen, 2006) . We argue that such a single-dimensional classification could be misleading. For example, a news article might report that an anti-cholesterol drug lowers cholesterol levels more effectively than do its competitors, but that some patients experience serious side-effects. This article could be coded as positive, negative, or neutral in a single-dimensional classification depending on the reader's perspective. To avoid ambiguity of context, we code the information of an article into a multi-dimensional attribute space. We consider three attributes for our drugs: (i) their ability to lower cholesterol levels (short-term efficacy); (ii) their ability to reduce the risks of heart disease (long-term efficacy); (iii) their side effects. Continuing with the above example, our algorithm would classify the article as positive in the dimension of lowering cholesterol levels and negative in the dimension of side effects. This multi-dimensional coding scheme can reduce measurement errors made in single-dimensional coding schemes used in the previous studies.
More importantly, it allows us to measure how different types of information may affect consumer demand. To the best of our knowledge, our research will be the first to use publicity data that is coded in such a precise fashion.
We implement our methodology to code the publicity data that are accessible in Canada. In addition to the publicity data, we have collected data on sales, detailing, journal advertising and clinical trial outcomes from 1993 to 2004. One potential advantage of using the data from the Canadian market is that direct-to-consumer advertising for prescription drugs is strictly regulated. While firms are restricted in their use of DTCA, they may have a stronger incentive to communicate directly with patients through publicity (e.g., by running more press releases). Therefore, the Canadian market may provide a more interesting setting for studying the roles of publicity.
We incorporate our multi-dimensional measure of publicity into a demand system generated from a standard discrete-choice demand model a la Berry (1994) . Consumer utility functions over drugs can be written as a function of product characteristics, including scientific evidence, publicity and other marketing activities. Market shares are then determined as the aggregate outcome of consumer utility maximizing decisions. Moreover, prices of prescription drugs are regulated in Canada. As a result, prices change very infrequently over time. This institutional setting has also made it easier for us to focus on studying how marketing communication activities would affect demand.
Our results suggest that not all forms of publicity are equal. We find that comparison articles are much more effective than non-comparison articles. Moreover, we find that the most effective type of publicity is to provide information on the cholesterol-lowering ability of the drug, and the second most effective type of publicity is about side-effects. Surprisingly, despite the ultimate goal of taking anti-cholesterol medication is to reduce heart disease risks, publicity related to this dimension has very little impact on demand for a particular drug. We also find evidence that physicians/patients may generalize clinical evidence on individual drug specific ability to reduce heart disease risks to the whole class of statins. The results suggest that manufacturers of the drugs which are more potent in reducing cholesterol could free-ride on the heart disease clinical evidence for other drugs. Our results could help firms decide which types of post-marketing clinical trials to invest.
The rest of this paper is organized as follows. Section 2 reviews previous literature. Section 3 describes background information including the Canadian health care system, regulations on the pharmaceutical industry, and the market for statins. Section 4 summarizes how we collect and code the publicity data. Section 5 reports the estimation results. Section 6 is the conclusion.
Literature Review
Most of the previous empirical studies on publicity focus on studying the impact of critics and product reviews on demand instead of media coverage (Basuroy et al., 2003; Berger et al., 2010; Chevalier and Mayzlin, 2006; Godes and Mayzlin, 2004) . The results of these studies appear to be ambiguous. While some studies indicate that positive (negative) information increases (decreases) product evaluation (Goldenberg et al., 2007; Huang and Chen, 2006) , others find evidence that publicity (product reviews) might increase sales of the product regardless of whether it is positive or negative (Berger et al., 2010) .
Our research is related to the growing pharmaceutical marketing literature, which focuses on studying the roles of detailing, journal advertising, DTCA and scientific evidence (Azoulay, 2002; Berndt et al., 1997; Calfee et al., 2002; Chan et al., 2010; Ching and Ishihara, 2010b; Cockburn and Anis, 2001; Iizuka and Jin, 2005; Liaukonyte, 2009 ). This literature seldom investigates the roles of media coverage. As far as we know, Chintagunta et al. (2009) is the only study that incorporate data on news coverage when estimating the demand for pharmaceutical products. However, their focus is to study learning through consumption experiences, and hence they simply incorporate publicity data as a control variable in their analysis. They classify publicity solely based on the titles of articles, and find puzzling results on the effect of their publicity variable. In particular, they find that news articles have a positive influence on prescription choice, regardless how the title sounds (positive, neutral or negative). They admit that this could be due to measurement error in their raw data or problems in the data coding design. Our coding methodology could potentially address the shortcomings of the literature mentioned above.
We should point out that our method is also related to the one proposed by Liaukonyte (2009) , who analyzes advertising content by classifying them as comparative and non-comparative advertising in the over-the-counter analgesics market. She finds evidence that the impact of comparative advertising on demand is more effective but shorter-lived than that of non-comparative advertising. However, for each classification, she still follows the traditional method by coding each article as positive, negative and neutral in a single dimension. Our multi-dimensional method of classification could provide richer results than does her approach.
Background

Health Care System in Canada
The Canada Health Act adopted in 1984 entitles all legal Canadian residents to receive medically necessary services without co-payment if the services are provided in hospital, or by practitioners. 3 While Canada's public health system covers drugs administered in a hospital, it does not cover outpatient prescription drugs costs, except for indigenous persons (i.e., First Nations and Inuit peoples), Canadian Forces members, veterans, Royal Canadian Mounted Police members, and inmates of federal penitentiaries. Moreover, provinces and territories administer publicly financed program to provide prescription drug coverage concentrated on seniors, disabled citizens, and low-income persons with special needs.
In 2004, according to the Auditor General of Canada, about one million Canadians were eligible for federal drug benefits and more than nine million were covered by provincial plans. About two-thirds of Canadian residents are covered for prescription drugs by private insurance obtained through their employer or purchased individually. Consequently, according to estimates for year 2000, 98% of the Canadian population has some form of public or private sector drug plan coverage that provides a degree of protection against severe drug expenditures (Fraser Group and Tristat Resources, 2002) .
Regulation of Price and Direct-to-Consumer Advertising for Prescription Drugs in Canada
In Canada, prices of patented prescription drugs are strictly regulated. Health Canada introduced a government agency, the Patented Medicine Prices Review Board (PMPRB) through amendments to the Patent Act in 1987. This board regulates drugs that are still under patent and which have no generic substitutes by establishing the maximum prices that can be charged in Canada for them (Anis and Wen, 1998; Paris and Docteur, 2006) . The PMPRB uses the term, "excessive" price, to characterize either a high introductory price of a new medication, or a substantial increase in the price of an existing medication. The essence of these regulations can be summarized as follows:
3 Health Canada http://www.hc-sc.gc.ca/hcs-sss/medi-assur/cha-lcs/index-eng.php 1. For a new strength or a new dosage form of an existing medicine, the price is considered excessive if it does not possess a reasonable relationship to the average price of the existing medicine.
2. For a drug that represents a therapeutic breakthrough or provides a substantial improvement over comparable existing medicines, the price is excessive if it exceeds the prices of all the comparable products in the therapeutic class and the median of the prices in seven countries: France, Germany, Italy, Sweden, Switzerland, the UK and the U.S.
3. For a drug that provides moderate, little or no therapeutic advantage over comparable medicines, the price is judged excessive if it exceeds the price of comparable products in the Canadian market.
PMPRB may use the median of the prices in seven countries as a reference when it is impossible or inappropriate to identify comparable drugs in Canada.
4. The change in price of existing medications is to be considered excessive if the price increase exceeds the increase in the general consumer price index.
DTCA is also regulated under Canada's Food and Drugs Act and Regulations. Health Canada currently allows two forms of advertising: (i) reminder advertisements, which include only the brand name and no health claims or hints about the product's use and (ii) disease-oriented or help-seeking advertisements, which do not mention a specific brand but discuss a condition and suggest that consumers ask their doctor about an unspecified treatment (Gardner et al., 2003 
The Market for anti-cholesterol drugs -Statins
There are two main types of cholesterols: LDL (the "bad" cholesterol) and HDL (the "good" cholesterol). High amounts of the bad LDL will deposit cholesterol on the artery walls forming plaques.
More and more plaques will narrow the arteries lumen and may eventually block blood flow, and lead to a heart attack. On the other hand, the good HDL takes excess cholesterol away and carries it back to the liver to be excreted. It can also remove some of the cholesterol already attached to the artery walls. Statins are a class of most commonly used anti-cholesterol drugs. They lower the level of LDL by blocking HMG-CoA reductase, which is the enzyme that synthesizes cholesterol in the liver.
Clinical research results have suggested that statins can also raise HDL by 5 to 10 percents. However some medical researchers argue that such modest increase may not have a significant positive effect in reducing the risks of heart disease. 4 Table 1 Crestor related side-effects, but it eventually declined the petition and concluded that it is not riskier 6 A positive correlation between high cholesterol levels and risks of coronary heart disease has been found in medical research. Nevertheless, a drug that can lower cholesterol levels effectively does not necessarily mean that it can reduce the risks of heart disease. For instance, a recent clinical trial shows that a new anti-cholesterol combination drug, Vytorin, does not reduce the risks of heart disease even though it is very effective in lowering cholesterol levels (Park, 2008) .
7 http://www.pslgroup.com/dg/5b8a2.htm than other statins on the market. Although safety issues for Crestor have been raised, Crestor has experienced strong growth in the pharmaceutical market. We next turn to describe our data.
Data
The analysis integrates three different data sources: (i) publicity data covering statins derived from Factiva, (ii) product level monthly prescription volume, detailing and journal advertising data for the Canadian statin market from IMS Canada, and (iii) landmark clinical trial data for statins.
Publicity Data
To investigate the impact of publicity on consumer demand, we collect publicity data covering statins newspapers with more than 500,000 daily circulations and the 25 top selling U.S. magazines. We assume that the public might not have direct access to the press release from news agencies. Therefore, we leave out articles from news agency such as Agence France-Presse, The Associated Press and Reuters. As a result, we include 7,002 articles in the analysis. For each article, we extracted data such as headline, source, contents and publication date. We detail our data collection approach in the appendix. To assess the impact of publicity on consumer demand, it is essential to construct appropriate measures of publicity. Since we often encounter articles which contain more than one message. Since an article can be positive in one dimension but negative in another for a drug, simply coding its overall tone as positive, neutral, or negative is likely to lead to ambiguity or measurement error. Therefore, we interpret each article along multiple dimensions: (i) the ability of the drug to lower cholesterol levels (short-term efficacy), (ii) the ability of the drug to reduce heart disease risks (long-term efficacy), and (iii) the drug's side effects. For each dimension, we label it as comparison if the article compares at least two statins, and non-comparison otherwise.
For non-comparison articles, we score each article using a three-step Likert scale (+1, 0, -1) to assess the positive, neutral or negative tone of the article, we assign "+1" ("-1") if the article favors (does not favor) the drug, and "0" if the article shows a neutral attitude toward the focal drug for each dimension. For example, "Lipitor reduces cholesterol levels fast," is counted as "+1" in the dimension of short-term efficacy, "Baycol can cause a fatal damage to patients' kidney" is considered to be "-1"
in the dimension of side effects, and "Pravachol was well-tolerated" is considered to be "+1" in the dimension of side effects.
The coding of comparison articles is somewhat more complicated. In order to capture all of the information contained in the message we score a comparison article according to the sum of its absolute and relative attitudes towards each drug cited in the article. For the absolute score, we assign each drug "+1", "0", or "-1" if the article shows a positive, neutral, or negative attitude towards the focal drug, respectively, as we do for non-comparison articles. For the relative score, we assign the focal drug the number of drugs that are reported inferior to the focal drug in the article. To illustrate how our algorithm works, we provide the following examples:
1. When an article reports that both Lipitor and Zocor lowered cholesterol levels but Lipitor did so more quickly than Zocor. For the absolute score, since the article states that both drugs are effective in lowering cholesterol levels (short-term efficacy), both of them are assigned "+1". For the relative score, since the article reports that Lipitor is more effective than Zocor, Lipitor is assigned "+1". Therefore, we code Lipitor as "+2" = 1 (absolute) + 1 (relative), and Zocor as "+1"= 1 (absolute) + 0 (relative) in the dimension of short-term efficacy.
When an article reports that Lipitor, Zocor and Pravachol were well-tolerated among patients in a clinical trial. Patients with Pravachol showed no significant side effects and less patients
experienced side effects with Lipitor than with Zocor, we code Pravachol as "+3" = 1 (absolute) + 2 (relative), Lipitor as "+2" = 1 (absolute) + 1 (relative), and Zocor as "+1" = 1 (absolute) + 0 (relative) in the dimension of side effects. 
Prescription Volume, Detailing and Journal Advertising Data
The product level data obtained from the market research firm, IMS Canada, consist of monthly observations of prescription volumes, detailing costs, and journal advertising pages for each statin The demand system used here will include an outside good (i.e., we allow patients with high LDL to choose treatments other than statins, or no treatment at all). We therefore need to calibrate the potential market size for statins, which includes high LDL patients who are on statins and other anticholesterol drugs, and those who choose not to take any drugs. In order to estimate what percentages of Canadians have a high cholesterol problem, we use data from the Canadian Heart Health Survey, recorded between 1986 and 1992. The study suggests that 33% of the total Canadian population aged 16 to 65 and 85% of that over 65 have a high cholesterol (i.e., high LDL) problem. We multiply this number by total Canadian population for each age group in a given month, as defined by the Statistics Canada, and use the result as a proxy for the total number of potential patients for statins. In order to convert total population with high cholesterol problem into the number of prescriptions, we assume that each patient visits a physician and receives a prescription once per 90 days. Based on this measure of potential market size, we calculate each brand's and outside good's market shares in each month.
For most product categories, price is an important factor that affects consumers' purchase decision on the product. However, we do not include prices in our demand system because the institutional details of Canada suggest that it may not play an important role. Price regulation for prescription drugs in Canada often leads to infrequent price changes. Table 6 shows the price which the province of Ontario pays for Ontario Drug Benefit program beneficiary. The table suggests that prices for statin have hardly changed over time, and this should alleviate the concern of price endogeneity (the data suggests that price is hardly correlated with unobserved demand shock that varies over time), and including brand fixed effects in our model should suffice in capturing the impact of prices. Moreover, around 98% of Canadian residents possess a certain type of coverage for prescription drugs.
Landmark Clinical Trials
Azoulay (2002) 
Econometric Model and Results
Model
We adopt the discrete-choice approach of Berry (1994) to model the demand for statins. This approach offers several benefits: the derived demand equations are consistent with consumer theory and the entry of new products can be easily incorporated. Consumer utility functions over drugs can be written as a function of product characteristics, including scientific evidence, publicity and other marketing activities. Market shares are then determined as the aggregate outcome of consumer utility maximizing decisions. We define the utility of a patient i when she buys an anti-cholesterol drug j at time t as follows:
where
goodwill stock of publicity, detailing and journal advertising, respectively; Landmark kjt denotes a dummy variable for landmark trial k for drug j at time t (Landmark kjt is equal to one if drug j receives a landmark trial k favoring its efficacy before time t, and zero otherwise); ξ jt may be interpreted as the mean of the consumer valuation of an unobserved product characteristic; ijt is assumed to be i.i.d.
extreme value distributed with mean zero across consumers. We normalize the mean utility of the outside good (j = 0) to be zero, and hence U i0t = i0t .
Detailing and journal advertising have been known to have long lasting impacts on demand (Azoulay, 2002; Berndt et al., 1997) . Therefore, in explaining current period sales, stocks of cumulative detailing, journal advertising, and publicity are more appropriate measures than flows. Following Azoulay (2002), we allow for the possibility that the stock variables decay over time with a monthly carryover rates of δ = .95. For example, the stock variable of detailing is defined as:
Since we assume that error terms ijt follow the extreme value distribution, the market share of drug j at time t is given by the logit formula:
It follows that,
where S jt is the market share of drug j; ξ jt are the unobserved characteristics of drug j at time t and become the error terms. Detailed descriptions of included variables are listed in each table of results.
Endogeneity of Detailing and Journal Advertising
The previous literature has recognized that detailing and journal advertising could be endogenous. A firm's detailing and journal advertising effort might be correlated with shocks to its drug's expected quality over time, which are unobservable to researchers. If a manufacturing firm observes these shocks, it is likely to choose a level of detailing and/or journal advertising to reflect the shock. Hence, if researchers do not incorporate the shock into the model, the coefficients on the detailing and journal advertising variables will be biased. We assume that clinical trial results and publicity are the major sources of information about the quality of drugs to consumers and physicians. There may also be some concern that publicity itself is endogenous. This is particularly true for articles that discuss sales of the drug. In other words, publicity might be correlated with unobserved shocks affecting sales of the drug. To address this concern we do not include articles purely related to sales of drugs (e.g., an article which reports that the sales of Lipitor have improved from the previous year) since we expect that the more popular drugs would have more meida coverage which emphasizes sales of the drug. The articles we include in our analysis refer to efficacy and side effects of statins and this type of publicity is generally yielded by the release of clinical trial results. In some broad economic sense, one can argue that these clinical trial results are correlated with unobserved shocks of sales over time. However, considering the time needed for publication and uncertain outcomes, we consider these clinical trial results and publicity as being uncorrelated with month-to-month changes in unobserved shocks. [only use the log regressions]. We take log of all the stocks of marketing and publicity variables when running these regressions. The literature has consistently found evidence that drugs are experience goods (Crawford and Shum, 2005; Ching, 2010a,b; Ferreyra and Kosenok, 2010) , and detailing activities contain information which helps the demand side to learn the true quality of the products (Ching and Ishihara, 2010b,a; Leffler, 1981; Narayanan et al., 2005) . When patients/physicians slowly learn the true quality of the products from consumption experiences, it is plausible that the marginal return of marketing activities would diminish over time. Our prior is that publicity serves a similar purpose, and hence it seems likely that its effects would also diminish over time. By taking logs of these variables, we are able to capture this feature.
Results
The first specification only includes stocks of detailing and journal advertising. It does not include any publicity variables. This regression serves as a benchmark for comparison. Consistent with the previous literature, we find that the effect of the detailing stock is positive and statistically significant.
The stock of journal advertising is much weaker -in fact, it is not significant.
The second specification includes the "traditional" type of publicity variables, where we do not break down the information content into a multi-dimensional attribute space. Instead, we simply have two variables: (i) comparison articles, and (ii) non-comparison articles. Under this traditional scheme, we code one article as positive (+1) when the sum of the three-step Likert scales across three dimensions is greater than zero, or negative (-1) when the sum is smaller than zero. These variables mimic the previous approach which codes articles in a single dimension fashion. The results show that the effect of the stock of comparison articles is positive and significant, while the effect of the stock of non-comparison articles is insignificant. Interestingly, the effect of the stock of journal advertising now becomes positive and significant. This may indicate that the first regression suffers from omitted variable bias.
In the third specification, we consider publicity about a drug along three dimensions: (i) its ability to lower cholesterol levels (LC); (ii) its ability to reduce the risks of heart disease (RH); (iii) its sideeffects (SE). We further distinguish whether the publicity is comparison or non-comparison, except for RH messages. For RH messages, we only consider non-comparison articles because the number of comparison articles is close to zero for RH. This is because there are very few (landmark) clinical trials which conduct head-to-head comparisons in this dimension. Although the ultimate goal of taking statins is to reduce risks of heart disease, it is possible that patients/physicians might mainly focus on the ability of drugs to lower cholesterol levels because it is well-documented that LDL and heart disease rates are positively correlated. It is important to empirically investigate whether this is the case because of its managerial and public policy implications. Our results show that the effect of the stock of LC comparison articles is positive and significant, while the effect of LC non-comparison articles is not significant. Interestingly, the effect of the stock of RH is not significant. The results support our hypothesis that patients/physicians mainly pay attention to the LC dimension. We also find that the effect of the stock of SE comparison articles is positive and significant. However, we find that the effect of SE non-comparison articles is negative and significant, which is counterintuitive.
Regarding LC comparison articles, we find that many articles are consistent in reporting the relative strength of statins in lowering cholesterol levels. It is common for articles to compare Lipitor with Mevacor, Lescol, Pravachol and Zocor -all of them are not as potent as Lipitor. Even though we have
given Lipitor an extra unit increase when coding such articles, 8 it might not be enough to reflect the additional benefits that Lipitor gets if we restrict the coefficient for LC comparison to be the same across drugs. Moreover, Baycol and Crestor are more potent than Lipitor, and they are introduced after Lipitor has been on the market for 1 year and 6 years, respectively. It turns out that most of the comparison articles involving Baycol and Crestor are typically comparing it with Lipitor. After reading these articles, it seems likely that at least some of the patients/physicians would infer that Baycol or Crestor is better than other statins as well. Since our coding scheme does not reflect this, the effect of LC comparison articles for Baycol and Crestor may be stronger than that for Lipitor.
Based on this intuition, we also allow LC comparison to have heterogeneous effects across drugs in the 8 When two drugs are compared, the more potent one receives +1 and the less potent one 0 for the measure of relativity.
fourth specification. The estimation results are consistent with our intuition. The point estimates of LC comparison are all positive and highly significant. The coefficient of Crestor and Baycol are close to each other, and higher than Lipitor. The differences are statistically significant. Moreover, the coefficient of Lipitor is much higher than those of other statins. Interestingly, the sign of the SE non-comparison variable now switches from negative to positive, and is statistically significant. This suggests that its negative coefficient in specification 3 could be due to misspecification bias. Nevertheless, the RH non-comparison variable remains insignificant.
In the medical literature, researchers believe that high cholesterol levels are an indicator for high risks of heart disease. A drug that can lower cholesterol levels would likely reduce risks of heart disease.
However, without a clinical trial that establishes a direct causal effect of taking the drug on heart attack incidence rates, its manufacturer is not allowed to directly tell doctors or advertise that the drug can reduce the risk of heart attack. Consequently, some drug companies are willing to sponsor landmark clinical trials to establish such evidence. Most of the RH articles report on clinical trial results. We therefore find it surprising that RH non-comparison variable is not significant. By investigating the medical continuing education literature, we find evidence that many physicians may not strictly follow evidence-based prescribing practice (Mamdani et al., 2008 ). It appears that some physicians may assume a drug's ability to lower the LDL level will likely translate to reducing heart disease risks and ignore the possibility that it may have other side-effects that work the other way. This could explain why the RH non-comparison variable is insignificant after controlling for LC.
Another possibilty is that physicians and patients generalize the ability of one drug to reduce heart disease risks to the whole statin class. In order to test this hypothesis, we estimate specification 5 where we create RH sum variable by summing RH non-comparison across drugs, taking the log, and allowing it to interact with the LC comparison variable. The interaction term is positive and significant, which supports our hypothesis. In specification 6, we allow the effects of the interaction term to differ across drugs. Because of the multi-collinearity issue, we do not allow the LC comparison variable to have heterogeneous effects across drugs. These interaction terms are all positive and significant except for Pravachol. Overall, the results from specification 6 are consistent with those of 4 and 5.
Previous studies that have investigated the impact of marketing-mix on sales in this market usually do not use clinical trial outcomes or publicity data with the exception of Azoulay (2002) what the previous studies did in our regressions. In particular, this is the first study that measures publicity in a multi-dimensional way. We therefore should alleviate the endogeneity problem of detailing due to omitted variables compared with previous studies.
We should also note that the correlation between journal advertising and detailing is quite high. The correlations are 0.824 and 0.721 for their flow and stock variables, respectively. Such high correlations suggest that it could be hard to separately measure their effects (Berndt et al., 1997) . This could explain why the point estimates of the stock of journal advertising vary across specifications. Since the estimate of the stock of detailing seems to be more stable. As a robustness check, we have run another set of regressions where we drop the stock of journal advertising. Most of the results reported above are robust in this specification. The results of this set of regressions are reported in tables 12 and 13 in the appendix. Venkataraman and Stremersch (2007) and Ching and Ishihara (2010a) find evidence that new indications or clinical evidence could change the effectiveness of detailing. We therefore consider an alternative specification where we allow the stock of detailing to interact with the clinical trial dum-mies. This allows us to capture the idea that the effect of detailing could be heterogeneous across drugs.
We find that our results regarding publicity are largely robust in this specification as well. The results of this set of regressions are reported in tables 14 and 15 in the appendix as well. 9
5.5 Do firms view publicity as substitute/complement for detailing and journal advertising?
As we mentioned in the introduction, publicity might serve as a substitute for detailing and/or journal advertising. As a test of whether this is the case, we regress detailing/journal advertising on the publicity variables. The results are reported in tables 9 and 10. Under specification 2 in table 9 for the detailing regression, we find that LC comparison and RH non-comparison variables are both positive and significant. In table 10 for the journal advertising regression, we find that the LC comparison variable is also positive and significant. If firms treat publicity as a substitute for detailing/journal advertising, we would expect that the coefficients for these variables should be negative. The positive coefficient could be due to the fact that most of the media coverage reports some new clinical findings.
As argued in the previous literature (Azoulay, 2002; Ching and Ishihara, 2010b) , the effectiveness of detailing/journal advertising may increases with positive clinical outcomes, and as a result, firms may also do more detailing. This may lead to the positive coefficients in these regressions.
We therefore run two more regressions for detailing/journal advertising response functions by controlling for the impact of landmark clinical trials. In specification 3 in tables 9 and 10, we simply include the clinical trial dummies which become one after the results from the trial have been released, but the dummy only applies to the focal drug. However, a clinical trial about drug A (say Lipitor) could affect the marketing activities for other drugs as well. Conceivably, if drug A receives good news, the marginal return of detailing for the rival drugs might decrease as it now becomes harder to convince doctors to switch away from drug A. We therefore allow the clinical trial dummies to affect drugs other than the ones being investigated in the trial. The results are reported in specification 4 in tables 9
and 10. In both specifications 3 and 4, we see that the publicity variables are no longer significant.
The results confirm our conjecture above. Moreover, they also indicate that firms' detailing or journal advertising decisions may not be influenced by publicity in general. 10 The coefficients for clinical trial dummies for both detailing and journal advertising estimating functions are reported in table 16 in the appendix.
Conclusion
This research attempts to study the role of publicity on the choice of prescription drugs. In the study we employ rich data sets to reduce a bias caused by omitted variables affecting the prescription choices.
The result presented here demonstrates that product market in the statin class is shaped by firms' detailing, journal advertising, publicity and scientific evidence.
By allowing the information that is provided in the text of publicity the model is able to show that different types of publicity have different impact on the choice of prescription drugs. The results also raise the interesting question of the extent to which publicity is a strategic instrument available to pharmaceutical companies. We will investigate this further in the future.
10 It is important to note that our analysis is at the product level. It is possible that firms' decisions to detail might change at the physician level in response to publicity Chen and Tan (2010). * denotes the drug which appears superior than compared statins in the study ** CURVES study is not a landmark study. Lipitor gained an approval from FDA with the study. Log of monthly stock of number of comparsion articles favoring drug j in the dimension of lowering cholesterol levels Log of monthly stock of number of non-comparsion articles favoring drug j in the dimension of reducing risks of heart disease Log of monthly stock of number of non-comparsion articles favoring drug j in the dimension of side effects Log of monthly stock of number of comparsion articles favoring drug j in the dimension of side effects
Interaction of monthly stock of number of comparison articles favoring drug j in the dimension of lowering cholesterol levels with sum of monthly stock of articles favoring any statin in the dimension of reducing risks of heart disease Log of monthly stock of detailing cost for drug j Log of monthly stock of medical journal advertising pages for drug j Log of monthly stock of number of non-comparsion articles favoring drug j Log of monthly stock of number of comparsion articles favoring drug j Log of monthly stock of number of non-comparsion articles favoring drug j in the dimension of lowering cholesterol levels 0.8496 Definition Number of months since the entry of the drug j Indicator variable representing whether patent for drug j expires at time t Indicator variable representing whether drug j is within four months of its entry at time t
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A Data Appendix
In this section of the appendix, we address the following issues: how to select articles and how to classify articles.
A.1 Selecting the Articles
We collected publicity data from Factiva, a famous information database service provider. Factiva website building language. Then, from each record, we extracted a headline, a source, contents and publication date and organize the data in our own MySQL database. Our web program and MySQL database provided at least two advantages. First, web-based program and database technology allowed us to easily make a change in coding scheme or modify the dataset. In this study, we employ a very large diverse dataset covering almost 20 year and we code them in a very sophisticated way. Therefore, we have to try a few different coding schemes to figure out the way which results in the least loss of the information embedded in publicity while coding the publicity. Since we were able to access, search, read, and modify the records conveniently through any web browser, we were able to code the publicity and manage the coded results very easily. Figure 7 depicts a screen shot for a list of articles in our sample. Because the publicity data was stored in a very organized way, we could search and read articles conveniently. These characteristics of our computer program made a big contribution in finding a proper coding scheme which is necessary to explain the impact of publicity. Second, we could save a large amount by fully utilizing the benefit of reading through computer screen. For example, we highlighted important keywords on screen with a different color. We colored statin names in red, clinical study names in blue and keywords related to efficacies or side effects in green. These highlighted keywords enabled readers to reduce time on reading articles by skipping the irrelevant parts and focusing on the sentences with important keywords. This trick seemed to save, at least, more than half of reading time.
Figure 8 depicts a screen shot for one article in our sample.
A.2 Classifying the Articles
Classifying articles was the very challenging part of our study for the following reasons. First, we often encounter multi-dimensional articles, which can be coded positive in one dimension but negative in another dimension. For example, one article could report that Crestor lowers cholesterol levels rapidly but might have a serious side-effects. If we had coded this article in a single dimension, it could have coded as positive if we emphasized the efficacy in lowering cholesterol levels or negative if we focus on the side-effects of the drug. Therefore, this single-dimensional coding scheme would lead to a measurement error. To reduce the possibility of bias caused by a single-dimensional coding scheme, we interpret each article along multiple dimensions: (i) lowering cholesterol levels (short-term efficacy),
(ii) reducing risks of heart disease (long-term efficacy), and (iii) side effects. For each dimension, we label an article comparison if the article compares more than two statins, and non-comparison if not.
We also provided detailed instruction on how to code articles. For non-comparison articles, we followed an approach previous research has adopted. We simply scored each article using a three-step Likert scale (+1, 0, -1) to assess the negative, neutral, or positive attitude of the article. However, we found that comparison articles cannot coded. Therefore, we code the data in a more complicated method than the non-comparison ones in order to avoid losing the information contained in the publicity. We score a comparison article with sum of two types of its attitudes towards the focal drug: absolute and relative. In an absolute level, we assign each drug "+1", "0", or "-1" if the article shows a positive, neutral, or negative attitude towards the focal drug, respectively, as we do for non-comparison articles.
For a relative level, we assign the focal drug the number of drugs that are reported inferior to the focal drug in the article. Second, we tried to keep loss of the information as little as possible. Some articles compare more than two drugs in their contents and if we had coded them simply positive and negative without considering the existing order among these drugs, we would have lost the information. Third, reducing personal difference across readers was a big challenge. Since we had to assess a very big body of publicity, we had to have multiple readers to classify articles and this task opened a high possibility of getting a big noise. Each reader could have a different impression on each article depending on his/her perspective. Therefore, we provided a clear instruction on how to code each article. By providing the detailed instruction, we try to minimized the chance of data collection noise.
B Robustness Check
The correlation between journal advertising and detailing is quite high, which are 0.824 and 0.721 for their flow and stock variables, respectively. Such high correlations suggest that it could be hard to separately measure their effects (Berndt et al., 1997) . This could explain why the point estimates of the stock of journal advertising vary across specifications. Since the estimate of the stock of detailing seems to be more stable. As a robustness check, we have run another set of regressions where we drop the stock of journal advertising. Most of the results reported in table 12 are robust in this specification compared to table 8.
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